Opinion|Videos|November 26, 2025
Key Objectives and Data from ASCENT-04
This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.
Advertisement
Episodes in this series
The ASCENT-04/KN-D19 study evaluated the efficacy of sacituzumab govitecan (SG) combined with pembrolizumab versus standard chemotherapy plus pembrolizumab in first-line treatment of metastatic TNBC. The study addressed a critical unmet need: improving outcomes in a population with historically limited options. SG has demonstrated benefit in the second-line setting, and combining it with immunotherapy upfront aimed to enhance clinical responses.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Reformulated Ranitidine After 5-Year Absence
2
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
3
FDA Approves Gene Replacement Therapy Itvisma for Patients With Spinal Muscular Atrophy
4
Update on Novel Antimicrobials and Their Uses
5
